ArticleScientific reports2025
Mechanistic insights into DEHP-induced progression of non-small cell lung cancer based on network toxicology and molecular docking.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Revealing key biomarkers and molecular mechanisms associated with di(2-ethylhexyl) phthalate in skin cancer.Frontiers in molecular biosciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Di(2-ethylhexyl) phthalate (DEHP), a widely used plasticizer, has been implicated in various health risks, including tumorigenesis. Non-small cell lung cancer (NSCLC), accounting for over 80% of lung cancer cases, remains a leading cause of cancer-related mortality. This study employed network toxicology and molecular docking to explore the molecular mechanisms underlying DEHP's toxic effects on NSCLC. DEHP and NSCLC targets were retrieved from CTD, SwissTargetPrediction, and GeneCards, yielding 225 overlapping genes. Protein-protein interaction (PPI) network analysis identified five core targets: TP53, JUN, SRC, AKT1, and ESR1. Gene Ontology (GO) and KEGG pathway enrichment analyses revealed significant involvement of the PI3K/AKT signaling pathway and regulation of apoptotic signaling in DEHP-induced NSCLC pathogenesis. Molecular docking confirmed strong binding affinities between DEHP and the core targets, with binding energies ranging from - 4.611 to -7.535 kcal/mol. These findings suggest that DEHP promotes NSCLC progression, metastasis, and chemoresistance through PI3K/AKT signaling and apoptotic pathway dysregulation. This study provides mechanistic insights into DEHP's role in NSCLC and highlights the need for public health interventions to mitigate DEHP exposure. Further experimental validation is warranted to strengthen these findings and guide the development of targeted therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.